Terbinafine Hydrochloride Market Intelligence, Analysis, and Forecast

I. Market Price Dynamics
Current Price Levels
As of May 2026, the market price of terbinafine hydrochloride remains at a high but stable level overall. Due to higher logistics efficiency, prices in the East China region are approximately 5%–8% lower than those in South China. On February 28, 2026, the quoted price for high-purity (≥99%) terbinafine hydrochloride API in Hubei Province stood at RMB 700–800 per kg; bulk procurement is subject to negotiation.

Causes of Price Fluctuations
1. Demand-side: In early March 2026, the approval and launch of HaiZheng Pharmaceuticals’ subsidiary product “Fenli Shu” (a veterinary formulation of terbinafine hydrochloride tablets) triggered a short-term surge in API demand, pushing spot prices in East China up by 2%–3%. However, this increase did not exceed historical highs.
2. Supply-side: Following GMP certification, API production capacity among East China-based manufacturers increased by 30%, effectively meeting export demand and alleviating supply tightness—thereby restraining sharp price increases.

II. Market Supply and Demand
Supply Situation
1. Capacity Expansion: In 2025, five new domestic registrations for terbinafine hydrochloride API were filed, all from enterprises that have obtained WHO Prequalification (PQ) pre-certification. The total number of registered APIs reached 23, representing a net increase of three over 2024. Enhanced production capacity in East China has strengthened overall supply capability.
2. Technological Advancement: Continuous-flow microreactor synthesis technology has entered pilot-scale production at Shandong Xinhua Pharmaceutical Co., Ltd., achieving a 13.6% improvement in yield versus traditional batch processes, reducing total impurities to 0.12%, and lowering unit energy consumption by 28%. If GMP certification is completed and large-scale commercialization achieved before 2026, this technology will further boost supply and reduce costs.

Demand Situation
1. Human Healthcare: Treatment of onychomycosis accounts for the largest share (42%), followed by tinea corporis and tinea cruris (28%). Accelerated standardization of clinical diagnosis and treatment in 2026—including an expected rise in tertiary hospital dermatology fungal specialty clinic coverage to 67.3%—will promote standardized prescribing behavior and improved patient medication adherence, thereby increasing demand for terbinafine hydrochloride.
2. Veterinary Market: Surging demand for pet dermatological infection treatments—especially for Microsporum canis—has driven an annual growth rate of 18% in the canine antifungal drug market. The launch of HaiZheng’s “Fenli Shu” fills a critical domestic gap in veterinary therapeutics, with projected veterinary segment revenue growth of 20% in 2026, further boosting API demand.

III. Competitive Landscape
Market Share of Key Enterprises
1. API Segment: Zhejiang Huahai Pharmaceutical holds the top position with a 22.1% market share; its 2024 revenue reached RMB 95 million, reflecting a 9.2% year-on-year increase.
2. Formulation Segment: Qilu Pharmaceutical (29.3% market share), CRH Pharm (19.3%), Jiangsu Hengrui Medicine (13.2%), and Zhejiang Huahai Pharmaceutical (11.6%) collectively account for approximately 73.6% of the domestic formulation market.

Domestic vs. International Competitive Dynamics
1. Multinational Enterprises: Novartis, GSK, and TEVA dominate the premium segment, collectively holding over 45% market share, leveraging brand strength and technological expertise.
2. Indian Enterprises: Dr. Reddy’s Laboratories and Cipla Ltd. compete aggressively in the mid-to-lower-tier segments via cost advantages, jointly commanding ~28% market share—exerting competitive pressure on domestic players.
3. Chinese Domestic Firms: Xiuzheng Pharmaceutical, Jilin Wantong Group, and Hubei Hengan Fulin Pharmaceutical are accelerating API exports; export volume rose 15% year-on-year in 2025, strengthening their competitiveness in global markets.

IV. Policy Environment Impacts
1. Medical Insurance Policy: Dynamic adjustment of the National Reimbursement Drug List (NRDL) has included oral terbinafine hydrochloride formulations under reimbursement coverage, enhancing patient affordability and stimulating market demand. In 2025, this product category accounted for 19.4% of all dermatological topical medications—a 3.2 percentage-point increase over 2020.
2. Regulatory Review & Approval Policy: In 2025, the National Medical Products Administration (NMPA) implemented an “immediate review upon filing” mechanism for terbinafine hydrochloride API registration, shortening the average review cycle from 142 working days in 2023 to 58 working days—a 59.2% improvement—accelerating time-to-market for new products and augmenting supply.
3. Green Production Standards: In June 2025, the Ministry of Ecology and Environment and the Ministry of Industry and Information Technology jointly issued the “Guidelines for Green Production of Chemical APIs (Trial)” — establishing mandatory limits for six core process parameters (e.g., palladium-carbon catalytic reduction, COD load in acidic wastewater) in terbinafine hydrochloride synthesis. This has driven a 12.7% year-on-year decline in unit-product comprehensive energy consumption, raising production costs while incentivizing technological upgrades and green transformation.
4. Export Policy: In 2025, the General Administration of Customs added terbinafine hydrochloride to the “White List for Expedited Clearance of Exported Pharmaceuticals”, granting priority treatment including advance declaration, priority inspection, and waiver of on-site verification. Average export clearance time decreased to 2.1 working days—down 44.7% year-on-year—facilitating expanded exports and enhanced international market share for domestic firms.

V. Analysis, Judgment, and Forecast
Short-Term (Next 6 Months)
Stimulated by newly approved veterinary product registrations, API demand will remain elevated for the near term, potentially driving prices up by 5%–8%. However, human healthcare formulation prices are expected to remain stable. As veterinary demand gradually stabilizes and domestic capacity continues expanding, upward price momentum will progressively moderate.

Long-Term (1–2 Years)
With sustained domestic capacity ramp-up and intensifying competition from Indian manufacturers, terbinafine hydrochloride prices are projected to retreat to a rational range, declining annually by 3%–5%. Domestically, the market size is forecast to reach RMB 2.45 billion in 2026 and surpass RMB 2.7 billion in 2027, with the veterinary segment’s share rising to 15%. Globally, the market is expected to exceed USD 10 billion by 2027, with long-acting formulations accounting for over 30% of total sales.

Future Development Trends
1. Technological Upgrading: Enterprises will intensify R&D efforts in advanced formulations—such as nanocrystal technology and sustained-release transdermal patches—to enhance gross margins and competitive differentiation.
2. Market Expansion: Companies will prioritize export growth in emerging markets—including Southeast Asia and the Middle East—to diversify policy-related risks.
3. Green Transformation: Firms will proactively adopt green manufacturing processes to meet environmental compliance requirements, reduce unit energy consumption and impurity levels, and strengthen global competitiveness.